Opioids
The Food and Drug Administration last week required certain labeling updates for opioid pain medicines in an effort to reduce unnecessary prescribing and prevent complications such as opioid-induced hyperalgesia, when an opioid causes an increase in pain or increased sensitivity to pain.
The Food and Drug Administration April 3 announced that it will require manufacturers of opioid analgesics used in outpatient settings to modify their Risk Evaluation and Mitigation Strategy within 180 days to make prepaid mail-back envelopes and educational materials on safe opioid disposal…
In response to Drug Enforcement Administration proposals to limit telehealth prescriptions for buprenorphine and other controlled substances after the COVID-19 public health emergency to a 30-day supply unless the prescriber or referring clinician have evaluated the patient in person, AHA today…
The Food and Drug Administration yesterday issued a report offering recommendations to address the opioid crisis and the role of analgesic oversight in preventing addiction, overdoses and deaths.
The AHA urges the DEA to release proposed rules for the Special Registration for Telemedicine as soon as possible. Doing so is necessary to ensure an appropriate feedback period and time for hospitals and health systems to comply with requirements.
The Food and Drug Administration recently updated its health care provider fact sheet on bebtelovimab to note that the monoclonal antibody is not expected to neutralize omicron subvariants BQ.1 and BQ.1.1.
The Centers for Disease Control and Prevention today released updated guidelines for clinicians prescribing opioids to outpatients for short- or long-term pain, which replace guidelines released in 2016.
UK HealthCare has been serving Lexington and its surrounding communities since 1962. Home to a Level I Trauma Center and a Level IV Neonatal Intensive Care Unit, UK HealthCare is committed to ensuring that every Kentuckian, no matter how sick they are, has access to quality care.
Hospitals and health systems must be clear on goals of their opioid stewardship program and intentional about a process for measuring and monitoring progress.
In this episode – part four of AHA’s five-part series on opioid stewardship – Marie Cleary-Fishman, AHA’s vice president of clinical quality, is joined once again by Holly Geyer, M.D., hospital internal medicine practitioner subspecialized in addiction medicine at Mayo Clinic. The discussion:…